Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9830230 | 0.86 | KMT2A (0.37) | HTTMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL116212 | 0.86 | HTT (0.37) | HTTMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL4734769 | 0.82 | MEN1 (0.34) | HTTMEN1KMT2APDE10A | |
| SCHEMBL18158244 | 0.78 | TSHR (0.33) | HTTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7298442 | 0.78 | KMT2A (0.34) | HTTMEN1KMT2APDK2 | |
| SCHEMBL16016862 | 0.78 | LMNA (0.41) | HTTMEN1KMT2ATDP1KDM4E | |
| SCHEMBL14161748 | 0.77 | MEN1 (0.31) | HTTMEN1KMT2A | |
| SCHEMBL21159332 | 0.77 | KMT2A (0.34) | HTTMEN1KMT2A | |
| SCHEMBL4647035 | 0.75 | KDM4E (0.59) | HTTMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL21542912 | 0.75 | FFAR2 (0.36) | HTTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 481 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226861-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2017-10-11 | — | — | EP | claimed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | claimed |
| EP-2586779-A1 | Process for the preparation of moxonidine | Hetero Research Foundation (IN) | 2013-05-01 | — | — | EP | claimed |
| US-20260146124-A1 | RESIN COMPOSITION AND USES OF THE SAME | TAIWAN UNION TECHNOLOGY CORPORATION (TW) | 2026-05-28 | — | — | US | disclosed |
| US-20260085154-A1 | POLYMER, COMPOSITION, CURED PRODUCT, LAMINATED BODY, AND ELECTRONIC COMPONENT | JSR CORPORATION (JP) | 2026-03-26 | — | — | US | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250365860-A1 | COPPER-CLAD LAMINATE AND USES OF THE SAME | TAIWAN UNION TECHNOLOGY CORP (TW) | 2025-11-27 | — | — | US | disclosed |
| US-12453731-B2 | Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-10-28 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3768260-B1 | OXADIAZOLE COMPOUNDS AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025084303-A1 | RESIN COMPOSITION, PREPREG, METAL-CLAD LAMINATE, AND METHOD FOR PRODUCING SAME | ＡＧＣ株式会社 | 2025-04-24 | — | — | WO | disclosed |
| EP-0857483-A1 | Substituted aminopyridines in the treatment of glucose metabolism disorders | ELI LILLY AND COMPANY (US) | 1998-08-12 | — | — | EP | disclosed |
| US-5732717-A | ADMINISTERING 4-CHLORO-5-(IMIDAZOLINE-2-YLAMINO)-6-METHOXY-2-METHYLPYRIMIDINE | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| WO-1997046241-A1 | FORMULATION AND METHOD FOR TREATING CONGESTIVE HEART FAILURE | ELI LILLY AND COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997035539-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-10-02 | — | — | WO | disclosed |
| EP-0768087-A2 | Treating substance abuse withdrawal | ELI LILLY AND COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
| US-4840662-A | HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1989-06-20 | — | — | US | disclosed |
| EP-0132826-B1 | N-(1-NITROPHENYL)-5-AMINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE | CIBA-GEIGY AG (CH) | 1988-09-28 | — | — | EP | disclosed |
| EP-0132826-A1 | N-(1-nitrophenyl)-5-aminopyrimidine derivatives, their preparation and use | CIBA-GEIGY AG (CH) | 1985-02-13 | — | — | EP | disclosed |
| US-4323570-A | HYPOTENSIVE AGENTS AND TREATING GLAUCOMA | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1982-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HTT 2514/4885MEN1 296/4885KMT2A 2069/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | HTT 2514/4885MEN1 296/4885KMT2A 2069/4885 |
| US-20260146124-A1 | RESIN COMPOSITION AND USES OF THE SAME | ARCN1, ASH2L, ITGA1 | HTT 3285/4885MEN1 1187/4885KMT2A 1264/4885 |
| US-12453731-B2 | Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof | MLLT1, WDR77, MLLT3 | HTT 4184/4885MEN1 1601/4885KMT2A 38/4885 |
| US-20260085154-A1 | POLYMER, COMPOSITION, CURED PRODUCT, LAMINATED BODY, AND ELECTRONIC COMPONENT | RER1, COL1A1, SMC1A | HTT 1064/4885MEN1 1024/4885KMT2A 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.